Synthetic Biologics Inc (SYN) Shares are Down -1.86%

Synthetic Biologics Inc (SYN) : During the past 4 weeks, traders have been relatively bearish on Synthetic Biologics Inc (SYN), hence the stock is down -6.38% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.36% relative to the S&P 500. The 4-week change in the price of the stock is -6.51% and the stock has fallen -1.86% in the past 1 week.

The stock has recorded a 20-day Moving Average of 4.88% and the 50-Day Moving Average is 7.91%.The 200 Day SMA reached 20.11%. Synthetic Biologics Inc. has dropped 24.4% during the last 3-month period . Year-to-Date the stock performance stands at -31%.


Synthetic Biologics Inc (NYSEMKT:SYN): The stock opened in the green at $1.59 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $1.64 and a low of $1.52 for the day. The stock did not find buyers even at the lows and closed at $1.58 recording a loss of -0.63%. 353,311 shares exchanged hands during the trading day. The stock had closed at $1.59 in the previous days trading.

Synthetic Biologics, Inc. is a clinical-stage biotechnology company. The Company is developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C) and a monoclonal antibody combination for the treatment of Pertussis. In addition, the Company is developing a Phase II oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.